| scholarly article | Q13442814 |
| P50 | author | Obi Griffith | Q30503239 |
| Malachi Griffith | Q37382147 | ||
| Christopher A. Miller | Q41044336 | ||
| Kilannin Krysiak | Q47502229 | ||
| Todd A Fehniger | Q57001106 | ||
| Melissa M Berrien-Elliott | Q57140352 | ||
| Matthew Matlock | Q58189124 | ||
| Nancy L Bartlett | Q60545128 | ||
| Brian S White | Q61159848 | ||
| Amanda Cashen | Q89209246 | ||
| Felicia Gomez | Q89475448 | ||
| P2093 | author name string | Robert S Fulton | |
| Catrina C Fronick | |||
| Kenneth R Carson | |||
| Friederike Kreisel | |||
| Lee Trani | |||
| P2860 | cites work | An integrated map of genetic variation from 1,092 human genomes | Q22122153 |
| cAMP-response-element-binding-protein-binding protein (CBP) and p300 are transcriptional co-activators of early growth response factor-1 (Egr-1) | Q24531306 | ||
| pH regulation and beyond: unanticipated functions for the voltage-gated proton channel, HVCN1 | Q24606285 | ||
| Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing | Q24612248 | ||
| Vma21p is a yeast membrane protein retained in the endoplasmic reticulum by a di-lysine motif and is required for the assembly of the vacuolar H(+)-ATPase complex | Q24619581 | ||
| VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing | Q24628978 | ||
| Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma | Q24630610 | ||
| Analysis of protein-coding genetic variation in 60,706 humans | Q26831376 | ||
| Transformed follicular non-Hodgkin lymphoma | Q26851974 | ||
| H1 histones: current perspectives and challenges | Q27023358 | ||
| Crystal structure of the Oct-1 POU domain bound to an octamer site: DNA recognition with tethered DNA-binding modules | Q27731280 | ||
| Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin | Q27851546 | ||
| MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. | Q27851888 | ||
| Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib | Q27853011 | ||
| Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry | Q27853195 | ||
| Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. | Q27853333 | ||
| Clustal W and Clustal X version 2.0 | Q27860517 | ||
| The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data | Q27860742 | ||
| The Sequence Alignment/Map format and SAMtools | Q27860966 | ||
| Inactivating mutations and overexpression of BCL10, a caspase recruitment domain-containing gene, in MALT lymphoma with t(1;14)(p22;q32) | Q28143651 | ||
| Bcl10 and MALT1, independent targets of chromosomal translocation in malt lymphoma, cooperate in a novel NF-kappa B signaling pathway | Q28206030 | ||
| OCA-B regulation of B-cell development and function | Q28208976 | ||
| Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia | Q28255147 | ||
| VMA21 deficiency prevents vacuolar ATPase assembly and causes autophagic vacuolar myopathy | Q28283153 | ||
| Signaling kinase AMPK activates stress-promoted transcription via histone H2B phosphorylation | Q28588964 | ||
| Inactivating mutations of acetyltransferase genes in B-cell lymphoma | Q29031276 | ||
| Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia | Q29614659 | ||
| Vacuolar ATPases: rotary proton pumps in physiology and pathophysiology | Q29614686 | ||
| Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads | Q29617402 | ||
| MuSiC: identifying mutational significance in cancer genomes | Q30418806 | ||
| Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders | Q33374851 | ||
| Genetics of follicular lymphoma transformation | Q33910446 | ||
| SomaticSniper: identification of somatic point mutations in whole genome sequencing data | Q34095911 | ||
| Mutational analysis of primary central nervous system lymphoma | Q34104139 | ||
| Analysis of the coding genome of diffuse large B-cell lymphoma | Q34205133 | ||
| Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs | Q34274529 | ||
| H2B Tyr37 phosphorylation suppresses expression of replication-dependent core histone genes | Q34293504 | ||
| Whole-genome sequencing identifies recurrent somatic NOTCH2 mutations in splenic marginal zone lymphoma. | Q34293927 | ||
| Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples | Q34327021 | ||
| Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. | Q34342958 | ||
| Acquired initiating mutations in early hematopoietic cells of CLL patients | Q34424293 | ||
| A targeted mutational landscape of angioimmunoblastic T-cell lymphoma. | Q34663596 | ||
| Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. | Q34752063 | ||
| BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma | Q35004965 | ||
| Mutations in early follicular lymphoma progenitors are associated with suppressed antigen presentation | Q35189915 | ||
| Genome Modeling System: A Knowledge Management Platform for Genomics | Q35836071 | ||
| Optimizing cancer genome sequencing and analysis | Q35863001 | ||
| Identification of two DNA-binding sites on the globular domain of histone H5. | Q35900412 | ||
| Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia | Q35903984 | ||
| The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development | Q36193517 | ||
| Whole exome sequencing of microdissected splenic marginal zone lymphoma: a study to discover novel tumor-specific mutations | Q36203511 | ||
| Pathogenesis of follicular lymphoma | Q36290288 | ||
| BTKbase: the mutation database for X-linked agammaglobulinemia. | Q36592292 | ||
| Evolution and impact of subclonal mutations in chronic lymphocytic leukemia | Q36619124 | ||
| Targeting early B-cell receptor signaling induces apoptosis in leukemic mantle cell lymphoma. | Q36649225 | ||
| Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics | Q36721503 | ||
| Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants | Q36913464 | ||
| Early growth response genes regulate B cell development, proliferation, and immune response | Q36992618 | ||
| GenVisR: Genomic Visualizations in R | Q37291788 | ||
| Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. | Q37318226 | ||
| Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma | Q37533656 | ||
| Therapeutic targeting of microenvironment in follicular lymphoma | Q38361629 | ||
| Germinal centres and B cell lymphomagenesis | Q38364884 | ||
| Is observation dead in follicular lymphoma? Still appropriate | Q38367313 | ||
| Follicular lymphoma: evolving therapeutic strategies | Q38779310 | ||
| Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells. | Q38930717 | ||
| Activating STAT6 mutations in follicular lymphoma. | Q38937478 | ||
| Oncogenic CARD11 mutations in human diffuse large B cell lymphoma | Q40005246 | ||
| mutation3D: Cancer Gene Prediction Through Atomic Clustering of Coding Variants in the Structural Proteome | Q40027634 | ||
| Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. | Q40183645 | ||
| The H2A/H2B-like histone-fold domain proteins at the crossroad between chromatin and different DNA metabolisms | Q40204864 | ||
| Coactivating factors p300 and CBP are transcriptionally crossregulated by Egr1 in prostate cells, leading to divergent responses | Q40540666 | ||
| Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas. | Q41066322 | ||
| Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma | Q41645565 | ||
| Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma | Q42696493 | ||
| The impact of race, age, and sex in follicular lymphoma: A comprehensive SEER analysis across consecutive treatment eras | Q46529052 | ||
| Recurrent mutations of NOTCH genes in follicular lymphoma identify a distinctive subset of tumours. | Q51119144 | ||
| Site-directed mutagenesis of the yeast V-ATPase B subunit (Vma2p) | Q70915145 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 473-483 | |
| P577 | publication date | 2016-11-14 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma | |
| P478 | volume | 129 |
| Q58611495 | A deep learning approach to automate refinement of somatic variant calling from cancer sequencing data |
| Q90482750 | Advances in targeted therapy for malignant lymphoma |
| Q90051698 | An EBNA3A-mutated Epstein-Barr virus (EBV) retains the capacity for lymphomagenesis in a cord blood-humanized mouse model |
| Q47561660 | Autoimmunity checkpoints as therapeutic targets in B cell malignancies |
| Q89128647 | CAR T cell therapy for B-cell lymphomas |
| Q104064730 | CXCR4 in Waldenström's Macroglobulinema: chances and challenges |
| Q47828228 | Chromatin modifying gene mutations in follicular lymphoma. |
| Q48298180 | Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors. |
| Q48185856 | Current prognostic and predictive factors in follicular lymphoma |
| Q99561773 | Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models |
| Q38372504 | Flow cytometric sorting coupled with exon capture sequencing identifies somatic mutations in archival lymphoma tissues |
| Q92185611 | Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs |
| Q39096389 | Follicular lymphoma, a B cell malignancy addicted to epigenetic mutations |
| Q48540269 | Follicular lymphoma: are we ready for a risk-adapted approach? |
| Q96640402 | Frequent mutations in the amino-terminal domain of BCL7A impair its tumor suppressor role in DLBCL |
| Q50107045 | From genetics to the clinic: a translational perspective on follicular lymphoma. |
| Q93182953 | Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016 |
| Q92832246 | Genomic landscape and chronological reconstruction of driver events in multiple myeloma |
| Q64087351 | Germinal center-derived lymphomas: The darkest side of humoral immunity |
| Q57034175 | IG--positive neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas |
| Q49489514 | IW-Scoring: an Integrative Weighted Scoring framework for annotating and prioritizing genetic variations in the noncoding genome |
| Q48248047 | Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets. |
| Q57909099 | Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes |
| Q92884419 | Noncovalent inhibitors reveal BTK gatekeeper and auto-inhibitory residues that control its transforming activity |
| Q90450796 | Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR |
| Q49888075 | Role of Bruton's tyrosine kinase in B cells and malignancies |
| Q47709959 | Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial. |
| Q56980480 | Standard operating procedure for somatic variant refinement of sequencing data with paired tumor and normal samples |
| Q49559913 | Successful treatment of follicular lymphoma with second-generation tyrosine kinase inhibitors administered for coexisting chronic myeloid leukemia |
| Q59808738 | The NOTCH Pathway and Its Mutations in Mature B Cell Malignancies |
| Q99418442 | The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy |
| Q62490013 | Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma |
| Q48592284 | Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia |
| Q90068162 | [Progress in the research of gene mutations in follicular lymphoma] |
Search more.